Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

NATIONAL HEALTH INVESTORS INC
Next earnings Aug 4, 2026 · consensus $0.88 EPS, $111M rev
Last earnings -1.3% on 2026-05-04
Revenue grew 47.1% YoY.
Quality fundamentals and an attractive price line up (~63% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0000877860, latest 10-Q filed 2026-05-04) · EODHD · as of 6/22/2026, 1:55:03 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
NATIONAL HEALTH INVESTORS INC shows $80.1M in FY2025 revenue (+47.1% YoY), a 177.6% net margin, and 9.3% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $35.8M | $48.8M | $54.4M | $80.1M |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $112M | $66.4M | $136M | $138M | $142M |
| Diluted EPS | $2.44 | $1.48 | $3.13 | $3.13 | $3.02 |
| Net margin | — | 185.5% | 277.9% | 253.6% | 177.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1 buy · 1 member · last 180d
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1483 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 2 open-market buys · 0 sales
| 2026-06-15 | MCCABE ROBERT A JR Director | Buy | 890.00 @ $71.65 | $63.8K |
| 2026-06-05 | Jobe James R Director | Gift | 225.00 | |
| 2026-06-05 | Mendelsohn D. Eric CEO and President | Buy | 1.50K @ $68.84 | $103K |
| 2026-05-05 | Spaid John L CFO/EVP Finance | Tax | 314.00 @ $73.09 | $23.0K |
| 2026-05-05 | Mendelsohn D. Eric CEO and President | Tax | 394.00 @ $73.09 | $28.8K |
| 2026-05-05 | Travis David L SVP/Chief Accounting Officer | Tax | 282.00 @ $73.09 | $20.6K |
| 2026-03-03 | Donohue Lilly Director | Award | 1.27K | |
| 2026-03-03 | COLDEN TRACY M J Director | Award | 1.27K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.